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Behavioral/Systems/Cognitive

cAMP Response Element-Binding Protein Deficiency Allows
for Increased Neurogenesis and a Rapid Onset of
Antidepressant Response
Tamar L. Gur,1 Alana C. Conti,1 Jessica Holden,1 Anita J. Bechtholt,2 Tiffany E. Hill,2 Irwin Lucki,1,2 Jessica E. Malberg,3
and Julie A. Blendy1
Departments of 1Pharmacology and 2Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and 3Neuroscience
Discovery, Wyeth Research, Princeton, New Jersey 08852

cAMP response element-binding protein (CREB) has been implicated in the molecular and cellular mechanisms of chronic antidepressant (AD) treatment, although its role in the behavioral response is unclear. CREB-deficient (CREB ␣⌬ mutant) mice demonstrate an
antidepressant phenotype in the tail suspension test (TST) and forced-swim test. Here, we show that, at baseline, CREB ␣⌬ mutant mice
exhibited increased hippocampal cell proliferation and neurogenesis compared with wild-type (WT) controls, effects similar to those
observed in WT mice after chronic desipramine (DMI) administration. Neurogenesis was not further augmented by chronic DMI treatment in CREB ␣⌬ mutant mice. Serotonin depletion decreased neurogenesis in CREB ␣⌬ mutant mice to WT levels, which correlated with
a reversal of the antidepressant phenotype in the TST. This effect was specific for the reversal of the antidepressant phenotype in these
mice, because serotonin depletion did not alter a baseline anxiety-like behavior in CREB ␣⌬ mutant mice. The response to chronic AD
treatment in the novelty-induced hypophagia (NIH) test may rely on neurogenesis. Therefore, we used this paradigm to evaluate chronic
AD treatment in CREB ␣⌬ mutant mice to determine whether the increased neurogenesis in these mice alters their response in the NIH
paradigm. Whereas both WT and CREB ␣⌬ mutant mice responded to chronic AD treatment in the NIH paradigm, only CREB ␣⌬ mutant
mice responded to acute AD treatment. However, in the elevated zero maze, DMI did not reverse anxiety behavior in mutant mice.
Together, these data show that increased hippocampal neurogenesis allows for an antidepressant phenotype as well as a rapid onset of
behavioral responses to AD treatment.
Key words: novelty-induced hypophagia; NIH; CREB; neurogenesis; DMI; mouse; depression

Introduction
Antidepressant (AD) treatment involves amelioration of symptoms over the course of weeks or months (Wong and Licinio,
2001). Chronic exposure to AD is accompanied by transcriptional and cellular modulation, occurring on a later timescale
than changes in monoamine levels and consistent with the onset
of the relief of symptoms (Frazer and Benmansour, 2002; Nestler
et al., 2002; Young et al., 2002; Carlezon et al., 2005; Blendy,
2006). In particular, the transcription factor cAMP response
element-binding protein (CREB) is upregulated after chronic AD
treatment; increases in CREB mRNA and protein, or phosphorylation of CREB have been shown in the hippocampus after
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chronic, but not acute AD administration (Nibuya et al., 1996;
Thome et al., 2000; Blom et al., 2002; Tiraboschi et al., 2004).
The significance of CREB regulation in mechanisms through
which chronic AD treatment produces symptomatic relief is unknown. Hippocampal atrophy is hypothesized to be one contributing factor to the affective and cognitive impairments observed
in depression (Watanabe et al., 1992; Stein-Behrens et al., 1994;
Magarinos et al., 1996; Sheline, 1996; McEwen, 1999; Sheline et
al., 2003). AD drugs that increase neurogenesis in the dentate
gyrus of the adult hippocampus plausibly counteract this pathology of depression (Malberg et al., 2000; Czeh et al., 2001; Manev
et al., 2001; Santarelli et al., 2003; Kodama et al., 2004; Sairanen et
al., 2005). CREB appears to play a role in neurogenesis, because
immature neurons in the adult hippocampus express phosphorylated CREB (Nakagawa et al., 2002b). Furthermore, transgenic
mice expressing a dominant-negative CREB mutation in the hippocampus demonstrated a reduction in neurogenesis (Nakagawa et
al., 2002a). The concurrent increases of both CREB and neurogenesis in the hippocampus in response to chronic AD treatment suggest that CREB may regulate hippocampal neurogenesis.
Although CREB may mediate molecular and cellular changes
induced by AD treatment, its role in modulating behavioral
responses to chronic treatment is still unclear. We previously
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reported that mice deficient in CREB (CREB ␣ ⌬ mutant)
(Hummler et al., 1994; Blendy et al., 1996) show a baseline decrease in immobility in the forced-swim test (FST) and tail suspension test (TST), behavioral models commonly used to evaluate AD efficacy (Lucki, 2001; Cryan et al., 2005). However,
immobility is further decreased with AD treatment (Conti et al.,
2002), suggesting that this acute behavioral response is mediated
by a CREB-independent mechanism. We examined neurogenesis
in these animals and showed that CREB ␣⌬ mutant mice had increased levels of hippocampal neurogenesis at baseline. Reductions in neurogenesis achieved by serotonin depletion in mutant
animals correlated with a reversal in the baseline antidepressant
phenotype of CREB ␣⌬ mutant mice in the TST, whereas wildtype (WT) mice did not show a change in either parameter. The
novelty-induced hypophagia (NIH) and novelty suppressed
feeding (NSF) paradigms are two closely related paradigms that
are responsive to chronic antidepressant treatment, and this behavioral response has been correlated with neurogenesis. In these
paradigms, latency to consume food in a novel environment is
measured and chronic but not acute AD treatment, as well as
acute benzodiazepine treatment, reduces the latency to feed in a
novel environment (Merali et al., 2003; Dulawa and Hen, 2005).
This effect of chronic antidepressant treatment, however, is diminished when neurogenesis is impaired (Santarelli et al., 2003).
This result suggests that the increase in neurogenesis associated
with chronic antidepressant treatment is required for the behavior associated with this paradigm. Therefore, we examined the
effect of chronic DMI administration using the NIH paradigm.
We found that, whereas both WT and CREB ␣⌬ mutant mice
responded to chronic AD treatment in this paradigm, only
CREB ␣⌬ mutant mice responded to acute treatment. Together,
these findings suggest that, in the absence of CREB throughout
development, an antidepressant phenotype emerges on both a
cellular and behavioral level.

Materials and Methods

Animals. CREB ␣⌬ mutant mice were backcrossed to the inbred mouse
strains 129SvEv and C57BL/6 for ⬎20 generations. For these experiments, WT and CREB ␣⌬ mutants were F1 hybrids obtained from crossing mice heterozygous for the CREB mutation from each strain. Mice
(3– 6 months of age; 20 – 40 g) were group housed and maintained on a
12 h light/dark cycle with food and water available ad libitum in accordance with the University of Pennsylvania Animal Care and Use Committee. For the NIH paradigm, mice were housed in groups of two. All
experimental testing sessions were conducted between 9:00 A.M. and
3:00 P.M., with animals randomly assigned to treatment conditions and
tested in counterbalanced order.
Drugs. p-Chlorophenylalanine methyl ester hydrochloride (PCPA), a
tryptophan hydroxylase inhibitor (250 mg/kg, i.p.) (Sigma, St. Louis,
MO) was dissolved in deionized water and injected twice daily for 3 d.
The last dose was administered 18 h before behavioral testing or killing
for neurogenesis. Desipramine (DMI) (12.5 mg/kg) (Sigma) was prepared immediately before use and injected intraperitoneally using a volume of 10 ml/kg. The dose was calculated as milligrams per kilogram of
the salt form and was dissolved in 0.9% saline. For acute treatment, mice
were injected with DMI or 0.9% saline in the morning and afternoon of
the day before, and morning of the day of testing, for a total of three doses
before exposure to the zero maze or NIH paradigm. For chronic treatment, mice were treated with DMI or saline twice daily for 3 weeks.
Tail suspension test. Eighteen hours after the final injection of saline or
PCPA, mice were individually suspended by the tail to a horizontal ringstand bar (distance from floor, 35 cm) using adhesive tape affixed 2 cm
from the tip of the tail. Mice demonstrated several escape-oriented behaviors interspersed with bouts of immobility as the session progressed.
A 6 min test session was videotaped and scored by a trained observer who
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was blind to the experimental conditions. The behavioral measure scored
was the duration of “immobility,” defined as the time when mice were
judged to cease escape-motivated behaviors.
Elevated zero maze. The zero maze (Stoelting, Wood Dale, IL) was
elevated 24 inches from the ground and consisted of two open areas (wall
height, 0.5 inches) and two closed areas (wall height, 12 inches). Each
mouse was placed in the closed area and the duration of testing was 300 s.
The Viewpoint Tracking System (Viewpoint, Champagne au Mont d’Or,
France) was used to video record and register the time spent in the open
areas and the number of entries into each area. Ethological parameters
[rearing, stretch-attend-posture (SAP), and head-dips] were scored
manually. The test was performed in dim lighting. Mice were acclimated
to the room for 1 h before testing. For the PCPA experiment, mice received the final dose of PCPA 18 h before testing. For the DMI experiment, mice received a total of three doses of DMI before testing (9:00
A.M. and 5:00 P.M. of the day before testing, and 9:00 A.M. on test day)
1– 4 h before testing.
Novelty-induced hypophagia. For 1 week before the training period,
and for the duration of the experiment, mice were housed in groups of
two. Training consisted of daily sessions in which mice were exposed to a
highly palatable food (peanut butter chips; Nestle, Glendale, CA) in a
clear plastic dish. Plastic dividers were placed inside each cage to separate
the mice during the training and home cage testing periods. Mice were
acclimated for 1 h before placement of food. Food was placed in the cage
for 15 min and latency to consume was measured. By the 12th day, a
baseline latency to approach the food dish was reached such that there
was ⬍20% variability between mice. For chronic antidepressant treatment, mice were injected for 25 d with 12.5 mg/kg DMI or 0.9% saline in
the morning (9:00 –10:00 A.M.) and afternoon (4:00 –5:00 P.M.). Testing
in the home, novel environment, and home environment occurred on
the last 3 d of injections.
For testing in the novel environment, mice were removed from the
home cage and placed in an empty standard cage with no bedding, which
was sprayed with a cleaner (Pine Sol) to emit a novel odor and was placed
in a white box with bright light illumination. Latency to consume was
recorded. These mice were tested 3– 6 h after DMI injection. Mice were
tested again in the home cage on the day after novel testing (Home 2),
under the same conditions as the first home test day (Home 1). In the
acute treatment experiment, training was performed as described above.
Mice were injected on the three testing days with 12.5 mg/kg DMI or
saline in the morning (9:00 –10:00 A.M.) and afternoon (4:00 –5:00 P.M.)
and testing occurred 3– 6 h after the morning injection of DMI. Thus, a
total of three doses of DMI were administered before exposure to the
novel environment.
Bromodeoxyuridine injections and tissue preparation. For evaluation of
the effect of DMI on short-term cell survival and bromodeoxyuridine
(BrdU) labeling, animals were administered saline or DMI (12.5 mg/kg,
i.p.; Sigma) twice daily for 38 d. Twenty-four hours after the last DMI or
saline injection, mice were administered BrdU twice daily (50 mg/kg, i.p.;
Zymed, San Francisco, CA) for 4 d. Twenty-four hours after the last BrdU
injection, mice were anesthetized and transcardially perfused (0.1 M cold
PBS for 5 min followed by 4% cold paraformaldehyde for 15 min). A
second set of animals were allowed to survive for 6 weeks after the BrdU
injection, at which time they were anesthetized and perfused for evaluation of long-term cell survival and phenotypic labeling. To determine the
effect of PCPA depletion on cell proliferation in CREB ␣⌬ mutant and
WT littermates, mice were perfused 2 h after a single BrdU injection (100
mg/kg). All brains were postfixed overnight in paraformaldehyde at 4°C
and stored at 4°C in 30% sucrose. Serial sections of the brains were cut
(35 m sections) through the entire hippocampus using a cryostat, and
sections were stored in 0.1% NaN3/PBS. This BrdU-labeling paradigm
has been successfully used in multiple laboratories to accurately
quantify labeled cells. In addition, the use of confocal microscopy
with BrdU and neuronal and glial markers allows for additional evaluation of neurogenesis.
Immunohistochemistry. Free-floating sections were used in the determination of BrdU labeling. Series of every ninth section through the
hippocampus or subventricular zone of the lateral ventricle were processed for BrdU immunohistochemistry (⬃10 –12 sections per brain).
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Using this spacing ensures that the same BrdU-positive cell will not be
counted twice. Sections evaluated for proliferation and neurogenesis
were heated for 20 min at 75°C in 0.01 M citric acid, pH 6.0, for antigen
retrieval. After washing in 0.1 M PBS, sections were permeabilized in 0.1%
trypsin with 0.1% CaCl2 for 10 min at room temperature. Sections were
rinsed with 0.1 M PBS and denatured with 2N HCl for 30 min at room
temperature. After blocking with 3% normal goat serum for 60 min at
room temperature, sections were incubated with anti-mouse BrdU (1:
150; Becton Dickinson, Franklin Lakes, NJ) with 0.5% Tween 20 overnight at room temperature. Sections were then incubated for 60 min with
secondary antibody (1:200 biotinylated goat anti-mouse IgG; Sigma)
followed by quenching of endogenous peroxidases with 3% hydrogen
peroxide for 15 min at room temperature. Secondary antibody signal was
amplified using an avidin– biotin complex (Vector Laboratories, Burlingame, CA) and visualized with DAB (Vector Laboratories).
For analysis of mature cell phenotypes, free-floating sections were
incubated in 2N HCl at 40°C for 20 min. Sections were rinsed in 0.02 M
potassium PBS (KPBS) and incubated with 0.3% Triton X-100 and 5%
normal goat serum in 0.02 M KPBS. Slices were incubated in primary
antibodies for 3 d at 4°C [1:100 anti-rat BrdU (Immunologicals Direct,
Raleigh, NC); 1:100 anti-mouse neuronal nuclei (NeuN) (Millipore, Temecula, CA); and 1:2500 rabbit anti-S100␤ (Swant, Bellinzona, Switzerland)]. After rinsing in KPBS, a 1:200 dilution of secondary antibodies
Alexa 488 anti-rat IgG (in goat), Alexa 633 anti-rabbit IgG (in goat), and
Alexa 568 anti-mouse IgG (in goat; highly cross absorbed) was applied
for 2 h at room temperature (Invitrogen, Eugene, OR). After washing,
sections were slide-mounted with ProLong antifade solution (Invitrogen) and stored under dark conditions at 4°C.
Immunohistochemical quantitation. All BrdU-labeled cells in the dentate gyrus (granule cell layer) were counted in each section by an experimenter blinded to the study code. To distinguish single cells within
clusters, all counts were performed at 40 and 100⫻ under a light microscope, omitting cells in the outermost focal plane. For the short-term
survival and proliferation cell counts (n ⫽ 6 – 8 per group), a cell was
counted as being in the subgranular zone (SGZ) of the dentate gyrus if it
was touching, or within the SGZ. Cells that were located more than two
cells away from the SGZ were classified as hilar. For long-term survival
cell counts (n ⫽ 6 – 8 per group), all BrdU-positive cells that were located
within the granule layer of the dentate gyrus were scored. Cells that were
located more than two cells away from the granule layer were considered
hilar. The total number of BrdU-labeled cells per section was determined
and multiplied by 9 to obtain the total number of cells per dentate gyrus.
For phenotypic analysis (n ⫽ 6 per group), triple-labeled slices (BrdU,
NeuN, S100␤) were analyzed using a Leica (Bannockburn, IL) TCS-NT
confocal microscope, and images were captured using Leica confocal
software. At least 50 BrdU-positive cells per animal were further analyzed
using z-plane sectioning in 1 m steps to confirm the colocalization of
both BrdU and either of the markers NeuN or S100␤. Cells were analyzed
in the xyz-plane using Imaris Software (Bitplane, Zurich, Switzerland).
Analysis of serotonin tissue content. Eighteen hours after the last injection of PCPA, mice were killed. Brains were rapidly microdissected, and
tissues were flash frozen in liquid nitrogen and stored at ⫺80°C until
analysis. Individual brain regions were homogenized in a 100 M ethylenediamine tetra-acetic acid solution dissolved in 0.1N perchloric acid
(15 l/mg of tissue). Samples were centrifuged at 2– 8°C for 15 min at
15,000 rpm and supernatant was filtered using 0.45 m nylon Costar
(Cambridge, MA) Spin-X centrifuge filters. HPLC coupled with electrochemical detection (EC) was used to assay the filtered supernatant for
serotonin content.
The HPLC-EC system (Bioanalytical Systems, West Lafayette, IN)
consisted of a PM-80 pump, a Sample Sentinel autosampler, and a LC-4C
electrochemical detector. Twelve microliters of sample were injected and
pumped through a reverse-phase microbore column (ODS; 3 m; 1 ⫻
100 mm; Bioanalytical Systems) at a flow rate of 0.6 ml/min with electrodetection at ⫹0.6 V. Separation for serotonin was accomplished by using
an HPLC mobile phase consisting of 90 mM sodium acetate, 35 mM citric
acid, 0.34 mM EDTA, 1.2 mM sodium octyl sulfate, and 9% methanol
(v/v) with the addition of 2% dimethlyacetamide (v/v). HCl (12N) was
used to adjust the pH of the mobile phase to 4.2.

Statistics. For the BrdU immunohistochemistry, ANOVA and Fisher
post hoc tests were performed to establish statistical significance. For the
PCPA/neurogenesis experiment, we applied a mixed-model analysis
(SAS Linux, version 9; Proc Mixed) with genetic group as a betweengroup factor and saline versus PCPA as a within-group factor. A post hoc
mixed-model contrast analysis was performed to test the hypothesis that
the CREB ␣⌬ mutant mice show increased neurogenesis in comparison
with other groups, comparing the saline-treated CREB ␣⌬ mutant mice
with all other groups. For the TST, we applied a mixed-model analysis
with genetic group as a between-group factor and saline versus DMI as a
within-group factor. A post hoc mixed-model contrast analysis was performed, comparing the saline-treated CREB ␣⌬ mutant mice with all
other groups, to test the hypothesis that the CREB ␣⌬ mutant mice
showed decreased immobility in comparison with other groups. For the
zero maze experiments, the ANOVA was performed on two genetic
groups (CREB ␣⌬, WT) by two treatment groups (SAL, DRUG), with
time in the open arm as a dependent variable. For the NIH paradigm
experiments, latency served as a dependent variable in a two genetic
groups (CREB ␣⌬, WT) by two treatment groups (SAL, DMI) ANOVA,
with condition (Home 1, Novel, Home 2) as a repeated-measures
(within) factor. The analysis was implemented in SAS (Linux, version 9;
Proc GLM).

Results
The antidepressant phenotype is associated with increased
cell proliferation in CREB-deficient mice
Chronic antidepressant treatment has been shown to increase
hippocampal neurogenesis. CREB ␣⌬ mutant mice demonstrate
antidepressant-like responses in tests such as the FST and TST,
which are readouts of antidepressant efficacy. To determine
whether altered neurogenesis may underlie the antidepressant
phenotype, we examined granule cell proliferation and neurogenesis in wild-type and CREB ␣⌬ mutant mice.
Animals were administered BrdU, and after different time
points of killing, the number of BrdU-positive cells in the adult
dentate gyrus was determined using immunohistochemical
detection.
At the 4 d time point, CREB ␣⌬ mutant mice exhibited significantly more BrdU-positive cells than respective WT controls
(F(1,23) ⫽ 5.24; p ⫽ 0.0316), corresponding to a 52% increase
(Fig. 1 A). In addition, chronic DMI treatment (5 weeks; 12.5
mg/kg, twice daily, i.p) was also examined. WT mice demonstrate
a significantly increased number of BrdU-positive cells in DMI
treated compared with saline controls by 51% (F(1,23) ⫽ 4.73; p ⫽
0.0402). However, DMI treatment did not further increase the
number of BrdU-positive cells in CREB ␣⌬ mutant mice compared with saline-treated mutant controls. The number of BrdUpositive cells in saline-treated CREB-deficient mice was comparable with that of DMI-treated WT mice.
The antidepressant phenotype is associated with increased
neurogenesis in CREB-deficient mice
To determine whether the newly born cells observed in WT and
CREB-deficient mice survive and differentiate into neurons, cells
labeled with BrdU were allowed to mature for 6 weeks. Salinetreated CREB ␣⌬ mutant mice exhibited significantly increased
numbers of BrdU-positive cells in the granule cell layer compared
with WT controls (F(1,24) ⫽ 12.49; p ⫽ 0.0017) (Fig. 1 B), suggesting that the many of the newly born cells survived for at least 6
weeks. In a similar manner, in WT mice, DMI treatment significantly increased the number of BrdU-positive cells compared
with saline-treated WT controls (F(1,24) ⫽ 5.098; p ⫽ 0.0033)
(Fig. 1 B) at this 6 week time point. However, in CREB ␣⌬
mutant mice, DMI had no additional effect on the number of
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Figure 2. Serotonin depletion reduced proliferation in CREB ␣⌬ mutant mice to WT levels.
CREB ␣⌬ mutant mice show a significant increase in cell proliferation compared with WT mice
( p ⫽ 0.0494). Treatment with PCPA (250 mg/kg) twice a day for 3 d reverses this increase
in cell proliferation in CREB ␣⌬ mutant mice to WT levels ( p ⫽ 0.0340), whereas PCPA
treatment had no effect on cell proliferation in WT mice (N ⫽ 5– 6). Error bars indicate
SEM. *p ⬍ 0.05; †p ⬍ 0.05.

Figure 1. A–C, CREB deficiency increases the number of BrdU-positive cells at 4 d (A) and 6
weeks (B) in the dentate gyrus, with the majority of BrdU-positive cells differentiating into
neurons (C). Saline-treated CREB ␣⌬ mutant mice demonstrated significantly increased number of BrdU-positive cells compared with WT controls (*p ⬍ 0.05; n ⫽ 6 – 8). This increase was
maintained at the 6 week time point, at which the majority of the BrdU-positive cells matured
into neurons, indicating a net increase in neurogenesis in the CREB ␣⌬ mutant mice. Chronic
DMI treatment significantly increased BrdU labeling in the dentate gyrus of WT mice at both
time points. The majority of the surviving cells matured into neurons, indicating a DMI-induced
increase in neurogenesis in WT mice. In contrast to the DMI-induced increase in neurogenesis
seen in WT mice, the CREB ␣⌬ mutant mice show no additional changes in BrdU labeling or
neurogenesis. Saline-treated CREB ␣⌬ mutant mice demonstrated comparable numbers of
BrdU-positive cells and neurogenesis with that of DMI-treated WT controls (*p ⬍ 0.05; n ⫽
6 –9). In all groups, the majority of surviving BrdU-positive cells expressed the neuronal marker,
NeuN. DMI treatment had no effect on the phenotypic distribution of surviving BrdU-positive
cells in WT or CREB ␣⌬ mutant mice. Error bars indicate SEM.

BrdU-positive cells. Similar to previous reports, the total
number of BrdU-positive cells after 6 weeks was lower compared with that at 24 h (Gould et al., 1999; Malberg et al., 2000;
Nakagawa et al., 2002a).

Phenotypic analysis of neurogenesis
To determine whether the BrdU-positive cells at the 6 week time
point have matured into neurons or glia, triple labeling with
BrdU, NeuN (marker for mature neurons), and S100␤ (glial
marker) was performed (Fig. 1C; supplemental Fig. 1, available at
www.jneurosci.org as supplemental material). Confocal microscopic analysis with z-plane sectioning confirmed that the majority of surviving BrdU-positive cells matured into neurons in all
groups. Phenotypic analysis revealed that 67 ⫾ 3% of the surviving BrdU-labeled cells in saline-treated WT mice expressed the
neuronal marker, NeuN. After DMI treatment, 66 ⫾ 6% of surviving BrdU-labeled cells exhibited a neuronal phenotype.
CREB ␣⌬ mutant mice demonstrated similar patterns of neuronal
differentiation, with 70 ⫾ 4% of surviving BrdU-positive cells
maturing into neurons in saline controls, compared with 76 ⫾
3% after DMI treatment. Fewer BrdU-labeled cells differentiated
into glial cells (Fig. 1C). In WT mice, saline controls demonstrated 10 ⫾ 2% of BrdU-positive cells with glial phenotypes as
did 12 ⫾ 2% after DMI treatment. In saline-treated CREBdeficient mice, 9 ⫾ 2% of BrdU-labeled cells expressed glial
markers, compared with 6 ⫾ 2% after DMI treatment. The remaining 18 –24% of BrdU-labeled cells were not labeled with
either NeuN or S100␤, indicating a population of quiescent, undifferentiated cells, or an existing cell type not labeled with the
antibodies used (Fig. 1C). BrdU, however, is not without its caveats (Eisch, 2002). BrdU may be taken up not only by proliferating cells but also by cells undergoing repair. Although we cannot rule out this possibility, it has been reported that this low level
of DNA incorporation is not easily detected using immunohistochemical methods (Palmer et al., 2000).
Together, these data indicate that CREB deficiency produces
an increase in BrdU-positive cells that survive for 6 weeks, and the
majority of those mature cells are neurons, indicating a net increase in neurogenesis.
Serotonin depletion decreased cell proliferation in CREBdeficient mice to WT levels
To examine the role of CREB deficiency and serotonin depletion
on cell proliferation, mice were treated with saline or PCPA, a
specific inhibitor of tryptophan hydroxylase, and killed 2 h after
the BrdU injection. This 2 h time point was chosen because it
represents one cell cycle of labeling (Cameron and McKay, 2001)
and is thought to be an accurate measure of cell proliferation
(Malberg et al., 2000). As shown in Figure 2, CREB ␣⌬ mutant
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Figure 3. Serotonin depletion reversed the antidepressant phenotype of CREB ␣⌬ mutant
mice in the TST. Mice were treated with PCPA twice a day for 3 d. Immobility in the TST was
measured 18 h after the last injection. The TST revealed a significant effect of genotype and
treatment, with the PCPA-treated CREB ␣⌬ mutant mice returning to WT levels (n ⫽ 4 – 8).
Error bars indicate SEM. *p ⬍ 0.05; †p ⬍ 0.05.

mice show an increase in BrdU-labeled cells. PCPA treatment led
to a reversal of this increase in CREB ␣⌬ mutant mice, whereas
PCPA had no significant effect on WT mice. A mixed model
statistical analysis found main effects for genetic group, (F(1,22) ⫽
4.35; p ⫽ 0.0494) and for treatment, (F(1,22) ⫽ 5.14; p ⫽ 0.0340).
Post hoc contrast analysis revealed that the hypothesized
(CREB ␣⌬ saline) group had significantly increased values compared with all other groups, (F(1,23) ⫽ 10.54; p ⫽ 0.0036). These
data indicate that CREB deletion increases cell proliferation,
which can then be decreased to WT levels by serotonin depletion.
Serotonin depletion increased immobility times of CREBdeficient mice to WT levels
To determine whether reversing the baseline increase in neurogenesis would have a functional behavioral correlate in the TST,
we administered PCPA to WT and CREB ␣⌬ mutant mice and
measured the effect on immobility. Mixed-model analysis found
main effects for genetic group (F(1,22) ⫽ 6.18; p ⫽ 0.0210) and for
treatment, (F(1,22) ⫽ 9.51; p ⫽ 0.0054). As shown in Figure 3,
CREB ␣⌬ mutant mice had significantly reduced values compared
with all other groups (F(1,24) ⫽ 10.10; p ⫽ 0.0041). This increase
demonstrates that the relationship between neurogenesis and behavior in these mice is maintained after serotonin depletion and
supports a causal relationship between neurogenesis and behavior in these mice.
Serotonin depletion has no effect on anxiety in the elevated
zero maze
In addition to an antidepressant phenotype, CREB ␣⌬ mutant
mice also exhibit increased baseline anxiety (Graves et al., 2002;
Hebda-Bauer et al., 2004). To determine whether the reversal of
neurogenesis and the antidepressant phenotype is accompanied
by a decrease in anxiety, we evaluated mice in the elevated zero
maze after serotonin depletion. As shown in Figure 4, treatment
with PCPA did not have an effect on time spent in the open arm
in either WT or CREB ␣⌬ mutant mice (F(1,30) ⫽ 0.06; p ⬎ 0.05),
with the latter once again demonstrating a baseline increase in
anxiety (F(1,30) ⫽ 6.76; p ⫽ 0.0143).
Serotonin levels are equivalent in WT and CREB ␣⌬
mutant mice
A possible explanation for the phenotype observed in CREB ␣⌬
mutant mice would be that the animals have altered serotonin
levels. Therefore, we measured tissue serotonin content in these
animals. Two-way ANOVAs demonstrate that the baseline serotonin level in CREB ␣⌬ mutant mice did not differ from that of
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Figure 4. Serotonin depletion does not have an effect on anxiety in the elevated zero maze.
Mice were treated with PCPA and tested in the elevated zero maze 18 h after the last dose.
CREB ␣⌬ mutant mice spent significantly less time in the open arm of the maze, reflecting a
proanxiety phenotype. Treatment with PCPA did not alter anxiety levels in either WT or CREB ␣⌬
mutant mice (n ⫽ 8 –9). Error bars indicate SEM. *p ⬍ 0.05.

WT mice throughout the amygdala, cortex, hippocampus, nucleus accumbens, and raphe (Table 1). 5-Hydroxy-indoleacetic
acid (5-HIAA)/5-HT ratios were measured as a marker for turnover, and no significant differences between mutants and WT
were found in the amygdala, cortex, hippocampus, nucleus accumbens, and raphe (Table 1). This suggests that baseline alterations in behavior and neurogenesis in CREB ␣⌬ mice are not
attributable to changes in serotonin or its turnover. Stimulated
serotonin release was also equivalent in WT and CREB ␣⌬ mutant
mice (supplemental Fig. 2, available at www.jneurosci.org as supplemental material), again demonstrating that CREB deficiency
throughout development does not impact serotonin metabolism.
The efficacy of PCPA treatment in these experiments was verified
by a 72–90% reduction in serotonin levels in comparison with
saline-treated animals: F(1,29) ⫽ 213.09, p ⬍ 0.0001; F(1,29) ⫽
217.51, p ⬍ 0.0001; F(1,29) ⫽ 148.14, p ⬍ 0.0001; F(1,27) ⫽ 24.54,
p ⬍ 0.0001; F(1,28) ⫽ 122.10, p ⬍ 0.0001, measured in the amygdala, cortex, hippocampus, nucleus accumbens, and raphe, respectively. The magnitude of PCPA depletion in discrete brain
regions was equivalent across genotypes.
WT and CREB ␣⌬ mutant mice respond to chronic
antidepressant treatment in the NIH paradigm
The NIH paradigm has been reported to be sensitive to chronic,
but not acute, antidepressant treatment. Therefore, we used this
paradigm to determine whether CREB ␣⌬ mutant mice respond
to chronic AD treatment. As shown in Figure 5, DMI significantly
reduced the latency to consume the food in a novel environment
for both WT and CREB ␣⌬ mutant mice. There was a main effect
of genotype with mutants showing overall higher latencies (F(1,34)
⫽ 4.78; p ⫽ 0.0358), an effect of treatment with treated mice
showing lower latencies (F(1,34) ⫽ 11.11; p ⫽ 0.0021), and no
genotype by treatment interaction (F(1,34) ⫽ 1.35; p ⫽ 0.2541).
Two-way ANOVA with repeated measures revealed a main effect
of condition with longer latencies for the novel compared with
home conditions (F(2,68) ⫽ 58.12; p ⬍ 0.0001), a genotype by
condition interaction with higher latencies for CREB ␣⌬ mutant
mice compared with WT in the novel condition (F(2,68) ⫽ 4.68;
p ⫽ 0.0125), a treatment by condition interaction with lower
latencies for DMI-treated mice in the novel condition (F(2,68) ⫽
12.21; p ⬍ 0.000), but no three-way interaction (F(2,68) ⫽ 1.42;
p ⫽ 0.2476). In addition, CREB ␣⌬ mutant mice had generally
increased latencies in the novel environment compared with WT
mice, consistent with the anxiogenic phenotype observed in the
zero maze (Fig. 4). Of the 40 mice tested, 2 were eliminated from
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Table 1. Serotonin tissue content (picograms per microliter) and turnover (5-HIAA/5-HT)
WT-saline
CREB␣⌬-saline

CREB␣⌬-PCPA

WT-PCPA

Brain region

Levels

Turnover

Levels

Turnover

Levels

Turnover

Levels

Turnover

Amygdala
Frontal cortex
Hippocampus
Nucleus accumbens
Brainstem

367 ⫾ 22
223 ⫾ 6
653 ⫾ 59
195 ⫾ 11
457 ⫾ 36

0.52 ⫾ 0.03
0.53 ⫾ 0.02
1.07 ⫾ 0.05
0.52 ⫾ 0.06
1.04 ⫾ 0.09

338 ⫾ 24
196 ⫾ 11
690 ⫾ 59
198 ⫾ 35
440 ⫾ 38

0.53 ⫾ 0.03
0.52 ⫾ 0.02
1.14 ⫾ 0.08
0.42 ⫾ 0.03
1.02 ⫾ 0.07

62 ⫾ 4
54 ⫾ 21
82 ⫾ 7
41 ⫾ 7
128 ⫾ 22

0.24 ⫾ 0.01
0.33 ⫾ 0.13
0.36 ⫾ 0.03
0.23 ⫾ 0.04
0.92 ⫾ 0.05

57 ⫾ 6
34 ⫾ 8
64 ⫾ 9
37 ⫾ 9
124 ⫾ 16

0.25 ⫾ 0.02
0.19 ⫾ 0.03
0.32 ⫾ 0.05
0.18 ⫾ 0.04
0.69 ⫾ 0.07

Mice (n ⫽ 8 –9 per group) were killed 18 h after the last injection of PCPA. Brains were microdissected and HPLC coupled with EC was used to assay the filtered supernatant for serotonin content. Baseline serotonin levels, turnover, and
depletion in CREB␣⌬ mutant mice did not differ from that of WT mice throughout the amygdala, cortex, hippocampus, nucleus accumbens, and raphe.

Figure 5. Chronic DMI treatment decreased the latency to consume peanut butter chips in
the novel environment in both WT and CREB ␣⌬ mutant mice. Mean latencies to consume the
highly palatable food in the home and novel environment are shown. Mice were treated with
DMI (12.5 mg/kg) for 25 d before testing. There was a decreased latency in DMI relative to
saline-treated animals (*p ⬍ 0.004). There was an overall increased latency in mutant relative
to WT animals (⫹p ⬍ 0.04) (n ⫽ 9 –10). Error bars indicate SEM.

analysis for having latency scores less than or greater than 2 SDs
from the mean.
CREB ␣⌬ mutant mice respond to acute antidepressant
treatment in the NIH paradigm
To control for the acute effects of AD in this paradigm, mice were
trained to consume a highly palatable food, and then injected on
the three testing days with 12.5 mg/kg DMI or saline in the morning (9:00 –10:00 A.M.) and afternoon (4:00 –5:00 P.M.). Testing
occurred at exactly the same time point after DMI as described
for the chronic experiment. As expected, acute DMI had no effect
on altering latency to consume food in a novel environment in
WT mice. In contrast, the time required by CREB ␣⌬ mutant mice
to investigate and consume the food was significantly reduced
(Fig. 6). The overall main effects of genetic group and treatment
group were replicated, with mutants showing overall higher latencies (F(1,24) ⫽ 4.90; p ⫽ 0.0366) and treated mice showing
lower latencies (F(1,24) ⫽ 9.40; p ⫽ 0.0053), but this time the
genotype by treatment interaction was also significant (F(1,24) ⫽
6.18; p ⫽ 0.0202). There was no treatment effect in the WT mice.
Two-way ANOVA with repeated measures showed a main effect
of condition (F(2,48) ⫽ 89.98; p ⬍ 0.0001) with longer latencies in
the novel condition, a genetic group by condition interaction
(F(2,48) ⫽ 4.64; p ⫽ 0.0143) with longer latencies in the CREB ␣⌬
mutant mice for the novel condition, a treatment by condition
interaction (F(2,48) ⫽ 9.86; p ⫽ 0.0003) with longer latencies in
untreated than treated mice, and these were accounted for by a
three-way interaction (F(2,48) ⫽ 6.86; p ⫽ 0.0024). The three-way
interaction indicates an effect of acute treatment in the CREB ␣⌬
mutant mice relative to the absence of treatment effects in the WT
mice. As seen previously (Fig. 5), saline-treated CREB ␣⌬ mutant

Figure 6. CREB ␣⌬ mutant mice demonstrated a significant decrease in latency in response
to acute DMI treatment, whereas there was no effect of treatment in the WT mice. Mean
latencies to consume the highly palatable food in the home and novel environment are shown.
Mice (n ⫽ 9 –10 per group) received a dose of DMI (12.5 mg/kg) in the morning and evening of
each of the 3 d of testing. A total of three doses of DMI was received before exposure to the novel
environment. There was a decreased latency in DMI relative to saline-treated CREB ␣⌬ mutant
mice (*p ⬍ 0.01). There was also an increased latency in mutant relative to WT animals (⫹p ⬍
0.04) (n ⫽ 7). Error bars indicate SEM.

mice demonstrated a significant increase in latency to approach
the food and eat over WT mice. Of the 33 mice tested, 5 were
eliminated from analysis for having latency scores less than or
greater than 2 SDs from the mean, or for failing to reach baseline
latency.
Increased baseline anxiety in the elevated zero maze is not
reversed in the CREB ␣⌬ mutant mice by acute antidepressant
treatment
To determine whether DMI had an anxiolytic-like effect in the
CREB ␣⌬ mutant mice, we tested this compound in the elevated
zero maze in WT and CREB ␣⌬ mutant mice. CREB ␣⌬ mutant
mice spent significantly less time in the open arm relative to WT
mice, reflective of an anxiety-like phenotype. However, this behavior was not mitigated by acute treatment with DMI (Fig. 7A).
Two-way ANOVA revealed a main effect of genotype (F(1,34) ⫽
20.71; p ⬍ 0.0001) on time spent in the open arm. Neither treatment nor genotype by treatment interaction approached significance on this parameter. In regard to ethologically relevant parameters and latency to enter the open arm (Fig. 7 B, C), two-way
ANOVAs demonstrated a significant effect of genotype on
stretch-attend-posture (F(1,34) ⫽ 5.93; p ⫽ 0.02), head dips
(F(1,34) ⫽ 10.904; p ⫽ 0.0023), and latency (F(1,34) ⫽ 4.237; p ⫽
0.0473), but not on rearing (F(1,34) ⫽ 0.026; p ⬎ 0.05). There was
no significant effect of treatment or genotype by treatment interactions on any of these parameters, including head dip, SAP,
latency, or rearing. Thus, the acute effect of DMI in CREB ␣⌬
mutant mice is specific to an antidepressant effect in these mice.
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Figure 7. A, CREB ␣⌬ mutant mice showed significantly reduced time spent in the open arm
relative to WT ( ⫹p ⬍ 0.0001) in the elevated zero maze. This reduction was not affected by
acute treatment with DMI. Mice (n ⫽ 9 –10 per group) received a total of three doses of DMI
(12.5 mg/kg) before testing, with the same schedule used in the NIH. B, In regard to ethologically relevant parameters, there is a significant effect of genotype on stretch-attend-posture,
and head dips (*p ⬍ 0.05), but not on rearing. C, CREB ␣⌬ mutant mice demonstrated an
increased latency to enter the open arm ( ⫹p ⬍ 0.05). Error bars indicate SEM.

Discussion
The notion that reduced hippocampal neurogenesis is involved
in the pathophysiology of depression has gained traction in recent years (Dranovsky and Hen, 2006; Duman and Monteggia,
2006). AD treatment is thought to ameliorate the symptoms of
depression by reversing this process. However, the connection
between neurogenesis, its molecular underpinnings, and behavioral consequences are mostly correlative. The FST and the TST
are commonly used to assess antidepressant effects of drugs and,
more recently, depressive phenotypes in mice (Cryan et al.,
2002). CREB ␣⌬ mutant mice demonstrated decreased immobility in both of these paradigms, which was further reduced by ADs
(Conti et al., 2002), suggesting an “antidepressant state” that is
still sensitive to drug treatment. Changes in homecage motor
activity or swimming behavior were not found (Walters and
Blendy, 2001; Graves et al., 2002), and therefore do not account
for these findings. To gather information on possible biological
substrates responsible for the antidepressant phenotype of
CREB ␣⌬ mutant mice, we examined neurogenesis, a parameter
altered by chronic AD treatment.
Our data demonstrate that constitutive reduction in CREB
protein enhances BrdU-labeled cell proliferation. Furthermore,
the majority of these cells mature into neurons, indicating that
CREB-deficient mice have increased proliferation and neurogenesis, comparable with levels observed in WT mice receiving
chronic AD treatment (Malberg et al., 2000). However, chronic
treatment with DMI did not further increase hippocampal neurogenesis in CREB-deficient mice. This lack of an additional
DMI-induced increase in neurogenesis in the CREB mutant mice
may be attributable to inherent proliferative limits of the hippocampus. In previous rat studies, treatment with fluoxetine increased the number of BrdU-labeled cells by 20 – 40%, whereas
electroconvulsive seizure caused a ⬃50% increase (Malberg et al.,
2000; Warner-Schmidt and Duman, 2007). Because CREB ␣⌬
mutant mice demonstrate an ⬃52% increase in BrdU-positive
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cells compared with WT mice, it is possible that the hippocampus
has reached the upper limits of its neurogenic capacity. Indeed, in
another mouse model showing 20% elevation in baseline levels of
hippocampal neurogenesis, chronic treatment with DMI and
citalopram failed to further increase neurogenesis (Morcuende et
al., 2003).
Our finding of increased levels of hippocampal neurogenesis
in the CREB-deficient mice (Fig. 1) differs from the report of
decreased levels in a transgenic mouse expressing dominantnegative CREB (mCREB) (Nakagawa et al., 2002a). However by
binding to CRE sequences in DNA, mCREB may target genes that
are not normally regulated by CREB (Blendy, 2006), thereby altering neurogenesis through other mechanisms. CREB manipulations in other mouse models, and viral vector-mediated gene
overexpression, have led to behavioral changes in depressionrelated behavioral paradigms as well. Acute overexpression of
CREB in the nucleus accumbens of rats leads to a pro-depressant
response in the FST, and a decrease of CREB mediated by expression of a dominant-negative form of the protein in rats leads to an
antidepressant-like effect (Pliakas et al., 2001), with similar effects found in the learned helplessness paradigm in mice and rats
(Newton et al., 2002). However, acute overexpression of CREB in
the hippocampus leads to an antidepressant effect in the FST
(Chen et al., 2001). To date, neither levels of neurogenesis nor
behavior in paradigms that are sensitive to chronic AD treatment
have been evaluated in these models.
To investigate a more causal relationship between neurogenesis, behavior, and CREB, we depleted mice of serotonin with
PCPA. Serotonin is thought to play a role in neurogenesis (Gaspar et al., 2003), and previous studies have reported either no
change or a decrease in proliferation in rats treated with PCPA
(Brezun and Daszuta, 1999, 2000; Banasr et al., 2001; Huang and
Herbert, 2005; Jha et al., 2006). Serotonin has been implicated in
both the pathophysiology and treatment of depression. Therefore, we wanted to examine the role of serotonin in maintaining
cell proliferation and antidepressant behavior in mice that demonstrate an antidepressant-like phenotype and increased levels of
neurogenesis. We found that serotonin depletion with PCPA reversed the antidepressant phenotype of CREB ␣⌬ mutant mice on
both a cellular (Fig. 2) and behavioral (Fig. 3) level, whereas it had
no effect on WT mice. Our data support previous findings that
PCPA depletion does not have an effect on immobility in WT
mice in the TST (O’Leary et al., 2007). Of interest, serotonin
levels and turnover did not differ between WT and CREB ␣⌬ mutant mice (Table 1) and stimulated release of serotonin was also
consistent between the two groups (supplemental Fig. 2, available
at www.jneurosci.org as supplemental material). However, the
serotonergic tone in CREB ␣⌬ mutant mice, although not different in magnitude, provides a critical stimulus that causes mice to
behave at baseline as though they have undergone chronic AD
treatment. Additional studies are warranted to investigate the
nature of this complex interaction.
In addition to an antidepressant-like phenotype, CREB ␣⌬
mutant mice demonstrate increased levels of anxiety (Graves et
al., 2002; Hebda-Bauer et al., 2004). This anxiety phenotype is
also evident in the NIH paradigm with CREB␣⌬ mutant mice
showing increased latency to feed in a novel environment (Figs. 5,
6). Serotonin depletion does not reverse the anxiogenic-like phenotype in the elevated zero maze (Fig. 4), further emphasizing a
specific correlation between the antidepressant phenotype and
neurogenesis. Whether PCPA treatment reduces the latency to
feed in a novel environment in CREB ␣⌬ mutant remains to be
seen. Unfortunately, serotonin depletion produces an anxiolytic,
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or decreased hyponeophagia effect in the NIH test in rat (Bechtholt et al., 2007), making it difficult to interpret baseline effects
in CREB ␣⌬ mutant mice.
Overall, the antidepressant-like phenotype may at first seem at
odds with the anxiety phenotype. However, 5-HT1A knock-out
mice also demonstrate an antidepressant phenotype in combination with an increased level of anxiety (Heisler et al., 1998; Parks
et al., 1998; Ramboz et al., 1998), suggesting that endophenotypes
related to comorbid neuropsychiatric disorders may be uncoupled in animal models.
To date, the significance of CREB in mediating any behaviors
associated with chronic AD treatment have not been investigated
in part because of the lack of well validated behavioral paradigms
designed to evaluate chronic AD effects. Therefore, to examine
the functional significance of increased neurogenesis as well as
gain additional insight into possible behavioral implications of
this alteration, we tested the CREB ␣⌬ mutant mice in the NIH
paradigm. In this paradigm, exposure to a novel environment
elicits an increased latency to consume a highly palatable food.
This increase in latency is reversed by chronic, but not shortterm, AD treatment (Merali et al., 2003), making it a useful model
to understand molecular and cellular changes underlying the behavioral response to chronic AD treatment. It is closely related to
the NSF paradigm, with the latter using food deprivation to induce consumption of regular food. A limitation of both the TST
and FST is their responsiveness to acute administration of antidepressants. Clinically, weeks of treatment are needed to ameliorate behavioral symptoms, reflecting the need for long-term transcriptional and cellular changes. Using the NIH paradigm, the
present data demonstrate that CREB ␣⌬ mutant mice respond to
acute AD treatment, an effect not seen in WT mice.
Acute anxiolytic compounds are effective in the NIH paradigm (Merali et al., 2003); thus the acute effect of DMI in the NIH
test in CREB ␣⌬ mutant mice could be interpreted as an
anxiolytic-like response. Caveats associated with constitutive
knock-out mouse models range from unexpected compensation,
effects on other gene products throughout development, and altered endocrine and neuronal feedback. These types of alterations in the CREB ␣⌬ mutant mice could result in a modification
of pharmacological profiles of classic AD. To determine whether
DMI is exerting anxiolytic effects in CREB ␣⌬ mutant mice, we
examined its effects on WT and CREB ␣⌬ mutant mice in a second
test for anxiety, the elevated zero maze. Few studies have examined the response to acute or chronic AD treatment in the elevated plus and elevated zero maze and results have been highly
variable. Depending on the test used and the AD administered,
many studies have reported no effect or an anxiogenic effect
(Borsini et al., 2002). Our results replicate the lack of efficacy of
acute DMI treatment in the elevated zero maze in WT mice.
Moreover, DMI is not effective in reducing anxiety in CREB ␣⌬
mutant mice, suggesting the acute action of DMI in the NIH test
may be more related to the antidepressant responsive aspects of
this paradigm.
AD effects in the NIH paradigm may require cellular changes
in response to AD treatment as well. In the NSF paradigm, it has
been shown that neurogenesis is necessary for a behavioral response to AD treatment (Santarelli et al., 2003). Thus, the increased levels of neurogenesis in CREB ␣⌬ mutant mice may provide a mechanism for the rapid onset of response to treatment
effects in these mice. Without the usual requirement of increasing
neurogenesis, AD drugs may exert behavioral effects more rapidly in an animal that has been “primed” to respond to these
compounds. Although CREB activation after AD treatment may
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serve to initiate mechanisms that underlie the lengthy time
course needed to achieve the behavioral effect in WT mice, under
conditions in which CREB is constitutively deleted these mechanisms are already engaged. Our findings have potential clinical
implications, because the delayed onset of a behavioral response
to AD treatment poses a challenge. Identification of mechanisms
through which CREB influences neurogenesis and the behavioral
response to AD treatment may identify new targets for fasteracting therapies for depression.

References
Banasr M, Hery M, Brezun JM, Daszuta A (2001) Serotonin mediates oestrogen stimulation of cell proliferation in the adult dentate gyrus. Eur
J Neurosci 14:1417–1424.
Bechtholt AJ, Hill TE, Lucki I (2007) Anxiolytic effect of serotonin depletion
in the novelty-induced hypophagia test. Psychopharmacology (Berl)
190:531–540.
Blendy JA (2006) The role of CREB in depression and antidepressant treatment. Biol Psychiatry 59:1144 –1150.
Blendy JA, Kaestner KH, Schmid W, Gass P, Schutz G (1996) Targeting of
the CREB gene leads to up-regulation of a novel CREB mRNA isoform.
EMBO J 15:1098 –1106.
Blom JM, Tascedda F, Carra S, Ferraguti C, Barden N, Brunello N (2002)
Altered regulation of CREB by chronic antidepressant administration in
the brain of transgenic mice with impaired glucocorticoid receptor function. Neuropsychopharmacology 26:605– 614.
Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety
predict anxiolytic-like effects of antidepressants? Psychopharmacology
(Berl) 163:121–141.
Brezun JM, Daszuta A (1999) Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats. Neuroscience 89:999 –1002.
Brezun JM, Daszuta A (2000) Serotonergic reinnervation reverses lesioninduced decreases in PSA-NCAM labeling and proliferation of hippocampal cells in adult rats. Hippocampus 10:37– 46.
Cameron HA, McKay RD (2001) Adult neurogenesis produces a large pool
of new granule cells in the dentate gyrus. J Comp Neurol 435:406 – 417.
Carlezon Jr WA, Duman RS, Nestler EJ (2005) The many faces of CREB.
Trends Neurosci 28:436 – 445.
Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS (2001) Expression of
the cAMP response element binding protein (CREB) in hippocampus
produces an antidepressant effect. Biol Psychiatry 49:753–762.
Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) cAMP response
element-binding protein is essential for the upregulation of brain-derived
neurotrophic factor transcription, but not the behavioral or endocrine
responses to antidepressant drugs. J Neurosci 22:3262–3268.
Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in
rodents: recent developments and future needs. Trends Pharmacol Sci
23:238 –245.
Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a
model for assessing antidepressant activity: review of pharmacological
and genetic studies in mice. Neurosci Biobehav Rev 29:571– 625.
Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M,
Bartolomucci A, Fuchs E (2001) Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by
antidepressant treatment with tianeptine. Proc Natl Acad Sci USA
98:12796 –12801.
Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by
stress and antidepressants. Biol Psychiatry 59:1136 –1143.
Dulawa SC, Hen R (2005) Recent advances in animal models of chronic
antidepressant effects: the novelty-induced hypophagia test. Neurosci
Biobehav Rev 29:771–783.
Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related
mood disorders. Biol Psychiatry 59:1116 –1127.
Eisch AJ (2002) Adult neurogenesis: implications for psychiatry. Prog Brain
Res 138:315–342.
Frazer A, Benmansour S (2002) Delayed pharmacological effects of antidepressants. Mol Psychiatry 7 [Suppl 1]:S23–S28.
Gaspar P, Cases O, Maroteaux L (2003) The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci
4:1002–1012.

7868 • J. Neurosci., July 18, 2007 • 27(29):7860 –7868
Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ (1999) Learning enhances
adult neurogenesis in the hippocampal formation. Nat Neurosci
2:260 –265.
Graves L, Dalvi A, Lucki I, Blendy JA, Abel T (2002) Behavioral analysis of
CREB alphadelta mutation on a B6/129 F1 hybrid background. Hippocampus 12:18 –26.
Hebda-Bauer EK, Watson SJ, Akil H (2004) CREB deficient mice show inhibition and low activity in novel environments without changes in stress
reactivity. Eur J Neurosci 20:503–513.
Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH
(1998) Elevated anxiety and antidepressant-like responses in serotonin
5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 95:15049 –15054.
Huang GJ, Herbert J (2005) Serotonin modulates the suppressive effects of
corticosterone on proliferating progenitor cells in the dentate gyrus of the
hippocampus in the adult rat. Neuropsychopharmacology 30:231–241.
Hummler E, Cole TJ, Blendy JA, Ganss R, Aguzzi A, Schmid W, Beermann F,
Schutz G (1994) Targeted mutation of the CREB gene: compensation
within the CREB/ATF family of transcription factors. Proc Natl Acad Sci
USA 91:5647–5651.
Jha S, Rajendran R, Davda J, Vaidya VA (2006) Selective serotonin depletion
does not regulate hippocampal neurogenesis in the adult rat brain: differential effects of p-chlorophenylalanine and 5,7-dihydroxytryptamine.
Brain Res 1075:48 –59.
Jones MD, Lucki I (2005) Sex differences in the regulation of serotonergic
transmission and behavior in 5-HT receptor knockout mice. Neuropsychopharmacology 30:1039 –1047.
Kodama M, Fujioka T, Duman RS (2004) Chronic olanzapine or fluoxetine
administration increases cell proliferation in hippocampus and prefrontal
cortex of adult rat. Biol Psychiatry 56:570 –580.
Lucki I (2001) A prescription to resist proscriptions for murine models of
depression. Psychopharmacology (Berl) 153:395–398.
Magarinos AM, McEwen BS, Flugge G, Fuchs E (1996) Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal
neurons in subordinate tree shrews. J Neurosci 16:3534 –3540.
Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant
treatment increases neurogenesis in adult rat hippocampus. J Neurosci
20:9104 –9110.
Manev H, Uz T, Smalheiser NR, Manev R (2001) Antidepressants alter cell
proliferation in the adult brain in vivo and in neural cultures in vitro. Eur
J Pharmacol 411:67–70.
McEwen BS (1999) Stress and hippocampal plasticity. Annu Rev Neurosci
22:105–122.
Merali Z, Levac C, Anisman H (2003) Validation of a simple, ethologically
relevant paradigm for assessing anxiety in mice. Biol Psychiatry
54:552–565.
Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, Fisher AS,
De Felipe C, Mantyh PW, Rupniak NM, Giese KP, Hunt SP (2003) Increased neurogenesis and brain-derived neurotrophic factor in
neurokinin-1 receptor gene knockout mice. Eur J Neurosci
18:1828 –1836.
Nakagawa S, Kim JE, Lee R, Malberg JE, Chen J, Steffen C, Zhang YJ, Nestler
EJ, Duman RS (2002a) Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein.
J Neurosci 22:3673–3682.
Nakagawa S, Kim JE, Lee R, Chen J, Fujioka T, Malberg J, Tsuji S, Duman RS
(2002b) Localization of phosphorylated cAMP response elementbinding protein in immature neurons of adult hippocampus. J Neurosci
22:9868 –9876.
Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002)
Neurobiology of depression. Neuron 34:13–25.
Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, Chen

Gur et al. • CREB and Antidepressant Response
J, Neve R, Nestler EJ, Duman RS (2002) Inhibition of cAMP response
element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 22:10883–10890.
Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365–2372.
O’Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007)
Depletion of serotonin and catecholamines block the acute behavioral
response to different classes of antidepressant drugs in the mouse tail
suspension test. Psychopharmacology (Berl) 192:357–371.
Palmer TD, Willhoite AR, Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425:479 – 494.
Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998) Increased anxiety
of mice lacking the serotonin 1A receptor. Proc Natl Acad Sci USA
95:10734 –10739.
Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon Jr WA
(2001) Altered responsiveness to cocaine and increased immobility in
the forced swim test associated with elevated cAMP response elementbinding protein expression in nucleus accumbens. J Neurosci
21:7397–7403.
Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ,
Brunner D, Hen R (1998) Serotonin receptor 1A knockout: an animal
model of anxiety-related disorder. Proc Natl Acad Sci USA
95:14476 –14481.
Sairanen M, Lucas G, Ernfors P, Castren M, Castren E (2005) Brain-derived
neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult
dentate gyrus. J Neurosci 25:1089 –1094.
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N,
Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of
hippocampal neurogenesis for the behavioral effects of antidepressants.
Science 301:805– 809.
Sheline YI (1996) Hippocampal atrophy in major depression: a result of
depression-induced neurotoxicity? Mol Psychiatry 1:298 –299.
Sheline YI, Gado MH, Kraemer HC (2003) Untreated depression and hippocampal volume loss. Am J Psychiatry 160:1516 –1518.
Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R (1994) Stress
exacerbates neuron loss and cytoskeletal pathology in the hippocampus.
J Neurosci 14:5373–5380.
Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS
(2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20:4030 – 4036.
Tiraboschi E, Tardito D, Kasahara J, Moraschi S, Pruneri P, Gennarelli M,
Racagni G, Popoli M (2004) Selective phosphorylation of nuclear CREB
by fluoxetine is linked to activation of CaM kinase IV and MAP kinase
cascades. Neuropsychopharmacology 29:1831–1840.
Walters CL, Blendy JA (2001) Different requirements for cAMP response
element binding protein in positive and negative reinforcing properties of
drugs of abuse. J Neurosci 21:9438 –9444.
Warner-Schmidt JL, Duman RS (2007) VEGF is an essential mediator of the
neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci
USA 104:4647– 4652.
Watanabe Y, Gould E, McEwen BS (1992) Stress induces atrophy of apical
dendrites of hippocampal CA3 pyramidal neurons. Brain Res
588:341–345.
Wong ML, Licinio J (2001) Research and treatment approaches to depression. Nat Rev Neurosci 2:343–351.
Young LT, Bakish D, Beaulieu S (2002) The neurobiology of treatment response to antidepressants and mood stabilizing medications. J Psychiatry
Neurosci 27:260 –265.

